Evidence map›Paper›PMID 41577890›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

Aztreonam plus ceftazidime/avibactam broth disk elution test: failure to detect Escherichia coli with PBP-3 insertions.

Gisele Peirano, Sydney D Walker, Mary S Duong, Kelsey Frank, Jan M Delantar, Luiz Lisboa, Wilson W Chan, Johann D D Pitout

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gisele PeiranoAlberta Precision Laboratories, University of Calgary, Calgary, AB, Canada.
Sydney D WalkerAlberta Precision Laboratories, University of Calgary, Calgary, AB, Canada.
Mary S DuongAlberta Precision Laboratories, University of Calgary, Calgary, AB, Canada.
Kelsey FrankAlberta Precision Laboratories, University of Calgary, Calgary, AB, Canada.
Jan M DelantarAlberta Precision Laboratories, University of Calgary, Calgary, AB, Canada.
Luiz LisboaAlberta Precision Laboratories, University of Calgary, Calgary, AB, Canada.
Wilson W ChanAlberta Precision Laboratories, University of Calgary, Calgary, AB, Canada.
Johann D D PitoutAlberta Precision Laboratories, University of Calgary, Calgary, AB, Canada. jpitout@ucalgary.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMetallo-β-lactamase (MBL)-producing Enterobacterales are increasing in frequency and treatment options are limited. Aztreonam/avibactam (AZA) and aztreonam (ATM) plus ceftazidime/avibactam (CZA) showed activities against these organisms. Escherichia coli with PBP3 insertions (YRIN, YRIK) showed decreased activities to AZA and have been linked with treatment failures.

methodsWe used well-characterized global collections of MBL-producing Enterobacterales (n = 86) to evaluate if MICs generated by AZA MIC Test Strips (MTS) could be used as substitute testing for ATM-CZA Broth Disk Elution (ATM-CZA BDE). We also determined if AZA (breakpoint of 4/4 µg/ml) or ATM-CZA BDE could detect E. coli with PBP-3 insertions.

resultsThe AZA MTS at ≤ 2/4µg/ml and ≥ 8/4µg/ml) showed 100% categorical agreement with ATM-CZA BDE but was less labour-intensive and more cost-effective. A strain with AZA MIC of 4/4 µg/ml tested not susceptible with ATM-CZA BDE, resulting in a very major error rate of 1/9 (11%). ATM-CZA BDE and AZA MICs (1-4 µg/ml) reported 76% (42/55) of E. coli with bla

conclusionsAZA MIC Test Strips can reliably predict ATM-CZA BDE results, except for strains with MICs of 4/4 µg/ml. ATM-CZA BDE failed to detect most of E. coli with PBP-3 insertions. E. coli with AZA MICs ranging from 1/4 to 4/4 µg/ml could be screened for PBP-3 insertions, and patients infected with such isolates, should be monitored for possible treatment failures with AZA or ATM-CZA.

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonamCeftazidimeEscherichia coliPenicillin-Binding Proteinsbeta-LactamasesDrug CombinationsHumansMicrobial Sensitivity TestsThird Generation CephalosporinsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsAztreonambeta-LactamasesCeftazidimeDrug CombinationsPenicillin-Binding ProteinsThird Generation CephalosporinsAztreonam/Avibactam gradient strip diffusionAztreonam- Ceftazidime/Avibactam broth disk elution methodE. coli PBP3 insertionsNDM

Identifiers

PMID41577890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.